KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.” The ONS abstract evaluated nur.

Business Wire • May 18, 2026

KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

KORU Medical Systems Announces First Quarter 2026 Results

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2026. The Company also reiterated guidance for the full year 2026. Recent Highlights First quarter 2026 net revenues of $11.8 million grew.

Business Wire • May 6, 2026

KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

KORU Medical Systems, Inc. (KRMD) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.

Zacks Investment Research • May 6, 2026

KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026

MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2026 financial results on Wednesday, May 6, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the.

Business Wire • Apr 16, 2026

KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump

KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.

Zacks Investment Research • Mar 17, 2026

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), ena.

Business Wire • Mar 13, 2026

KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript

KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 12, 2026

KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights Fourth quarter 2025 net revenues gre.

Business Wire • Mar 12, 2026

KORU Medical Systems Announces CEO Transition

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalberma.

Business Wire • Mar 12, 2026